Vimarsana
Biggest News Aggregation in the World

Ca Eprx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ca Eprx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ca Eprx Today - Breaking & Trending Today

Eupraxia Initiates Second Cohort in Clinical Trial in Eosinophilic Esophagitis - Vimarsana News

Eupraxia Initiates Second Cohort in Clinical Trial in Eosinophilic Esophagitis

Published: October 11, 2023

By Robb M. Stewart Eupraxia Pharmaceuticals has initiated the second cohort for its early-stage trial in eosinophilic esophagitis as it continues to make...

Source: marketwatch.com
Related Topics:
Robbm StewartEupraxia PharmaceuticalsArticle NormalScientific Research ServicesHealthcare Life SciencesBusiness Consumer ServicesMedical Research ServicesDrug Discovery DevelopmentHealthcare Support ServicesDiagnostic Medical Research ServicesNew Products ServicesResearch DevelopmentCorporate Industrial NewsProducts ServicesNew Product Service TestingContent TypesFactiva FiltersC Amp Ampe Industry News FilterEprx TCa EprxNew ProductsIndustrial NewsNew ProductService TestingLife Sciences
Eupraxia Pharmaceuticals Shares Climb With Plans for Private Placement - Vimarsana News

Eupraxia Pharmaceuticals Shares Climb With Plans for Private Placement

Published: August 4, 2023

By Robb M. Stewart Eupraxia Pharmaceuticals' shares advanced Friday after the biotechnology company moved to raise up to 22 million Canadian dollars ($16.5...

Source: marketwatch.com
Related Topics:
Robbm StewartArticle NormalBiotechnology ServicesScientific Research ServicesHealthcare Life SciencesBusiness Consumer ServicesMedical Research ServicesDrug Discovery DevelopmentHealthcare Support ServicesDiagnostic Medical Research ServicesCorporate FundingCorporate Industrial NewsPrivate PlacementsContent TypesFactiva FiltersC Amp Ampe Industry News FilterEupraxia PharmaceuticalsEprx TCa EprxIndustrial NewsLife SciencesConsumer ServicesDrug Discovery